ProRx Semaglutide Injection Recall: Risk of Contamination
ProRx recalls Semaglutide injections with potential contamination risk. Affected lots have specific batch numbers and expiration dates. Consumers should contact ProRx for details.
Recall notice
Lack of Assurance of Sterility
Contact the company
What happened, in plain English
ProRx is recalling certain Semaglutide injections due to a lack of assurance of sterility. This means the product could be contaminated, posing a risk of infection after injection. Read more at govinfonow.com/recall/31693-prorx-semaglutide-injection-recall-risk-of-contamination.
Source Summary by GovInfoNow · govinfonow.com/recall/31693-prorx-semaglutide-injection-recall-risk-of-contamination · Updated August 18, 2026 · FDA enforcement record: FDA #D-0115-2026
Cite this page
“ProRx Semaglutide Injection Recall: Risk of Contamination.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/31693-prorx-semaglutide-injection-recall-risk-of-contamination. Based on FDA recall #D-0115-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0115-2026%22&limit=1).
Why it’s dangerous
The product lacks assurance of sterility, meaning it could be contaminated with bacteria or other pathogens. If injected, this could lead to infections or other health issues.
Who’s affected
People who have been prescribed Semaglutide injections by a doctor and received the recalled lots. Those with the specific batch numbers listed are most at risk.
How to tell if you have this one
Check the product label for the batch numbers: PRORX050925-1, PRORX051425-5, or PRORX051425-6. The expiration date (BUD) for these lots is November 4, 2025 or November 10, 2025.
- Brand
ProRx- Category
Drug
All 7 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Ongoing- Distribution
TX and UT
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-0114-2026 | Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09; Lot# Prorx04282025-3 | 2,809 vials |
| D-0115-2026 | Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04; Lot, Best Use Date (BUD): Lot PRORX050925-1, BUD November 4, 2025; Lot ProRx051425-5, BUD November 10, 2025; Lot ProRx051425-6, BUD November 10, 2025 | 8,400 vials |
| D-0116-2026 | Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08; Lot Prorx051425-2, Lot Prorx051425-3 and Lot Prorx051425-4 | 8,310 vials |
| D-0117-2026 | Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09; Lot Prorx051525-1, Prorx051525-2, Prorx051525-3 and Prorx051525-4 | 11,119 vials |
| D-0118-2026 | Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-06; Lot Prorx051525-5 | 2,649 vials |
| D-0119-2026 | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02; Lot PRORX052125-4 | 2,805 vials |
| D-0120-2026 | Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-209-03; Lot PRORX08062025-3 | 2,761 vials |
What to do — step by step
Check Product Label
Look for the batch numbers: PRORX050925-1, PRORX051425-5, or PRORX051425-6 on the vial.
Where it went and when
Where it was distributed
Distributed in Texas and Utah.
FDA distribution: “TX and UT” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Texas, Utah.
Recall timeline
FDA published this recall 21 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0115-2026 (October 15, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0115-2026 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.